08:00 | Registration and refreshments | |
WELCOME AND OPENING REMARKS | ||
08:45 | Opening Remarks | Dr Samir Agrawal |
SESSION 1: KEYNOTE LECTURE - CANDIDA AURIS (NOW AND THE FUTURE) | ||
Chair: Dr Nelesh Govender | ||
08:55 | TBC | Dr David Perlin |
09:25 | Technical break (5 minutes) | |
SESSION 2: CURRENT STATE OF ANTIFUNGAL RESISTANCE SURVEILLANCE | ||
Chair: Dr Rohini Manuel | ||
09:30 | Candida Resistance – UK Epidemiology | Dr Colin Brown |
09:50 | Emerging Antifungal Resistance in Africa | Dr Nelesh Govender |
10:10 | Global Antifungal Surveillance and Future Perspectives | Dr Paul Verweij |
10:30 | Q&A | All |
10:45 | Coffee break and poster viewing | |
SESSION 3 : ANTIFUNGAL PROPHYLAXIS IN HAEMATO-ONCOLOGY | ||
Chair: Dr Johan Maertens | ||
11:00 | Antifungal Prophlyaxis in Haematology | Dr Jannik Stemler |
11:20 | Diagnosis vs Prophylaxis - The BioDrive AFS Study | Dr Gavin Barlow |
11:40 | Q&A | All |
11:55 | Technical break (5 minutes) | |
SESSION 4: SPONSORED SYMPOSIUM | ||
Chair: Malcom Richardson | ||
12:00 | TBC | TBC |
12:30 | Lunch break and poster viewing | |
SESSION 5: SPONSORED SYMPOSIUM | ||
Chair: Dr Mansour Ceesay | ||
13:30 | TBC | TBC |
14:00 | Technical break (5 minutes) | |
SESSION 6: MEET THE PATHOGEN | ||
Chair: TBC | ||
14:05 | Trichophyton Indotineae | TBC |
14:25 | Species within the Aspergillus Fumigatii complex, that are difficult to ID and have high MIC’s to AFT | Dr Ana Alastruey-Izquierdo |
14:45 | Emergomyces | Professor Ilan Schwartz |
15:05 | Q&A | All |
15:20 | Technical break (5 minutes) | |
SESSION 7: PCP DIAGNOSTICS: THE PAST, PRESENT AND FUTURE | ||
Chair: Professor Sean Wasserman | ||
15:35 | Panel discussion including Q&A | Dr Jay Kolls, Dr Riina Richardson |
16:10 | Technical break (5 minutes) | |
SESSION 8: CLINICAL CONUNDRUMS - MANAGING RESISTANT IFIS IN PRACTICE | ||
Chair: Dr Tihana Bicanic | ||
16:15 | Case 1: Paediatric | Dr Andreas Groll |
16:35 | Q&A | |
16:40 | Case 2: ICU | TBC |
17:00 | Q&A | |
17:05 | Case 3: Haematology/Oncology | Dr Neil Stone |
17:25 | Q&A |

Categories:
Tags:
Comments are closed